Detalhe da pesquisa
1.
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Invest New Drugs
; 39(4): 1019-1027, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507454
2.
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Cancer
; 125(14): 2400-2408, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30951193
3.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35210307
4.
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
J Clin Oncol
; 38(16): 1797-1806, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271672
5.
A urologic perspective on management of localized and metastatic RCC.
Oncology (Williston Park)
; 26(6): 537, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22870538
6.
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Clin Cancer Res
; 23(14): 3557-3565, 2017 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28031424
7.
Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.
Blood
; 99(4): 1486-8, 2002 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11830505